Albireo Pharma Inc

+0.29 (+0.88%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)636.68M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.98 Million
Adjusted EPS-$1.98
See more estimates
10-Day MA$32.77
50-Day MA$31.78
200-Day MA$35.21
See more pivots

Albireo Pharma Inc Stock, NASDAQ:ALBO

10 Post Office Square, Suite 1000, Boston, Massachusetts 02109
United States of America
Phone: +1.857.254.5555
Number of Employees: 90


Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-G?¶ran Gillberg on December 8, 2003 and is headquartered in Boston, MA.